



MOBI | O  
I N T E R A C T I V E

---

Supporting  
health systems  
with unbiased data  
and scalable care.

---



# Highlights

- ✓ Unmatched accuracy in objective quantification of psychological stress at scale
- ✓ Versatile & clinically validated mobile health platform with product-market fit
- ✓ Team deeply experienced in healthcare, neuroscience, and business
- ✓ Respected and recurring health systems clients across multiple markets

**Pre-A fully-raised and closed (US\$2M)**



# Clinical & Commercial Strategy

## All mental health is youth mental health

The vast majority of mental health challenges in adults can be traced back to childhood/adolescence.

Mobio has discovered adolescents to be highly responsive patients for its digital mental health solutions. (e.g., Mobio's clinically validated intervention for acute traumatic brain injury in adolescents has a NPS score of 100.)

Financial resources from Mobio's upcoming Series A will focus on LIC and LMIC market entry, as well as increasing access to quality mental healthcare for adolescents worldwide.



# Team



Dr Bechara Saab, CEO & Chief Scientist

- Former Principal Investigator, Zurich Psychiatry Hospital
- Canadian W.E.F. "Future World Leader"
- 50+ peer-reviewed pubs; 2,100+ citations; 80+ talks worldwide
- Fellow, Royal Society of Medicine
- 3<sup>rd</sup> time founder & CEO; 1 exit; 2 thriving
- PhD, Neuroscience, Mt. Sinai Hospital, Toronto



Santhya Iyngkaran, Clinical Experience Lead

- Licenced Clinical Psychologist
- Fellow, Singapore Psychological Society
- 5 years experience developing scalable clinical programs for adolescents and adults
- Masters of Clinical Psychology, UCSI University



Jon Brilliant, CFO

- CFO, of Welldoc (raised \$50m+; lead deals w/ AstraZeneca, Sanofi)
- Co-founder and CFO, Bigfoot Biomedical (sold to Abbott, \$370m)
- Senior Advisor at Merck Global Healthcare Fund
- Co-founder, Managing Director, CFO of Atelier Group (\$65m fund)
- Juris Doctor, High Honours, Duke University



Steve Carenevale, Growth Advisor

- Commercialisation strategy
- Mental Health Commissioner, State of California
- Founder and co-Chairman, UCSF Dyslexia Center



Prof Walter Greenleaf, Scientific Advisor

- Behavioural science
- Research Scientist, Stanford
- Former Director, Mind Division, Stanford
- Advisory Board Member, Altoida



Michael Meissner, Growth Advisor

- Healthcare strategy
- Former GM, Cardiac Rhythm Management, Medtronic
- Former CTO, MedTech, Sanofi
- Former Chairman of the Board, Scrum Alliance

Plus another 10 full-time staff, 5 part-time staff, and over 100 contributing Advisory, Directors, Psychiatrists, Clinical Psychologists, and other qualified Healthcare Professionals and experts. At Mobio Interactive, we maintain a superstar in every seat: <https://www.mobiointeractive.com/full-team>



# Market

Global mental healthcare expenditure:  
\$1.8T


Accessible to Mobio's business model:  
\$500B

Obtainable by Mobio at maturity:  
\$50B

MOBIO

2027 ARR:

\$11M





## Global Mental Health Crisis

It is no secret that demand for clinical mental health services far outstrips supply.



1B

### Demand: Everywhere

- The WHO estimates 1 in 8 people alive today need mental health services, and more than 1 in 2 will require mental health services at some point in their lives
- Youth are particularly in need, with suicide rising to the second leading cause of death between the ages of 10 and 25
- Many conditions have no approved therapy protocol

??

### Supply: Missing data, scarce, expensive

- Without objective data, finding the right solution for a patient can take months or even years
- In-person psychotherapy is expensive and cannot scale to the demand
- Pharmacotherapy has limited efficacy and negative side-effects
- Non-clinical tools lack efficacy and integration into the healthcare economy, limiting access



## AmDTx

AI native patient-facing mobile health platform that quantifies mental health in real time without bias while delivering clinically validated care at scale.



### Base platform for remote patient monitoring + patient & clinical decision support

- Accurate and objective measure of psychological stress without a wearable
- EMR-integrated remote patient monitoring and clinical decision support
- Patient wellbeing aid via 1,000+ medical-grade psychotherapy audio recordings in 7 languages
- Patient-specific personalisation
- Customisable + SDK/API solutions



### Prescription interventions:

- AmDTx can unlock indication-specific regulatory-cleared and fully reimbursed Class II SaMD interventions
- Each intervention is a clinically validated step-by-step psychotherapy course, engaged by patients asynchronously and on-demand
- Choice of intervention is made by a physician, via the clinic EMR integrated with AmDTx (single-click prescription mechanism)



# Verticals

Laser focused on platform commercialisation via two complimentary verticals:



## Health Systems Licensing

- Four major hospital clients signed and revenue-generating (two in Canada, two in Singapore)
- Average ARR per hospital: \$55k USD
- Covers unlimited patient onboarding, backend integration with EHR
- Bespoke platform augmentation charged separately
- 2024 target revenues: \$500k



## Remote Monitoring

- One key initial telehealth client signed and revenue generating (USA)
- Average MRR per patient: \$10 (can grow to \$200)
- Conservative estimate of 6 months of monitoring per patient
- Consistent, highly scalable MRR
- Simple to replicate
- 2024 target revenues: \$100k

These verticals are the fastest route to the most revenue. They strategically increase platform use by patients and physicians, which is important for additional verticals launching in 2025.



# Existing Clients Examples



## **CAMH (Centre for Addiction and Mental Health)**

- Psychiatric teaching hospital in Toronto, plus 10 community centres across Ontario
- World-respected psychiatric research, incl. discovering the D2 dopamine receptor
- Licensing AmDTx to support psychiatric patients on waitlist, with >200 currently monitored and receiving care



## **CHEO (Children's Hospital of Eastern Ontario)**

- Major tertiary children's hospital treating 260k patients annually with 2k physicians
- Global leader in "beyond hospital walls" program
- Licensing AmDTx to support paediatric psychiatric patients, with >50 currently monitored and receiving care



## **Neuroglympse**

- Neurology/psychiatry specialist telehealth provider in the USA
- Exceptionally innovative in the automation of patient data visualisation and procedure billing
- Distributing AmDTx for remote monitoring, with >150 patients currently reimbursed



## **Institute of Mental Health**

- Largest provider of mental health services in Singapore, with 50 wards and >2000 beds
- Only tertiary hospital in Singapore with psychiatric services
- Licensing AmDTx to support and monitor patients on waitlist, launching 24Q2 with 140 patients



## **Singapore General Hospital**

- Largest hospital in Singapore with 50 wards and >2000 beds and caring for 1 million patients annually
- Oldest and considered the "National" hospital of Singapore
- Licensing AmDTx to support and monitor patients on waitlist, launching 24Q2 with 60 patients



# Client Testimonials



**Prof. Dr. Alexander Daros, Centre for Addiction and Mental Health**

*"The potential of the Mobio Interactive platform is that people can do something that will help their mental wellbeing, while also feedback information to clinicians... to understand how that person is doing without having to subjectively ask them every week or every two days."*



**Prof. Dr. Gary Goldfield, Children's Hospital of Eastern Ontario**

*"We think DTx have the potential to remediate or address that massive disparity in supply and demand for services, as well as providing evidence-based care"*



**Brett Landrum, CEO, Neuroglympse**

*"What we love about the AmDTx platform is the unique combination of scientific rigor, versatility, customisation, and - most important for our patients - scalability."*





# Traction





26 Hospitals,  
4 Telehealth



## Business



## Clinical Validation



















































## Data





# Competitive Landscape

The only digital health platform that objectively quantifies mental wellbeing in real time while delivering clinically validated interventions without a wearable.

	Objective <u>mental</u> health measures	Objective health measures	Free from wearables	All-in-one platform	Multiple indications	Validated against placebo
 <b>AmDTx</b>						
LUCID   HelloBetter 						
 binah.ai   						
    Respiree  						
   						




# Competitive Edge

M O B I O  
I N T E R A C T I V E

A unique, large, high-quality dataset powerful enough to train AI to objectively quantify psychological states from a 30 s smartphone selfie

- HRV
- SpO<sub>2</sub>
- Bilirubin
- Melanin
- Breath Rate
- $\beta$ -Carotene
- Microexpressions
- Facial Blood Distribution




from the human face to objectively quantify brain states.



>150 nations represented  
across >25,000 individuals

425+ thousand 30 s selfie scans providing  
3.5+ million unique and useful\* datapoints  
(growing every hour)



\*By "unique and useful", we refer to complete measures of a biological process from a real person captured over the course of a 30 s average.


\*\*By "informed", we refer to people trained in meditation and other contemplative practices, rendering their self-reports of wellbeing more accurate than the average individual.



# An Unbiased Measure of Psychological Stress

Psychological stress is the best available proxy for overall mental and physical health – when measured objectively – and thus a critical tool to guide clinical practice and personalise therapy for the population.

Using our unique dataset to train AI  
(self-developed 6-layer deep neural network)




12% greater accuracy and 15-fold lower error rate compared to the standard HRV algorithm


**Table 3** Accuracy of stress prediction for classification DNN, chance and other methods

Method	Accuracy	MSE
Classification DNN	86%	-
Prediction DNN	-	0.02
Chance	32%	-
Logistic Regression	77%	0.31
SVM	43%	-
HRV <sub>HIGH</sub> /HRV <sub>LOW</sub>	32%	1.45

Works for all skin tones



Proof of personalised care benefits  
from real world study with 2,876  
patients in 80 countries






# Clinical Partners






# Clinical Trials (mostly RCTs)


All stages: **44**




Completed: **17**



Active: **4**




Preparing launch: **23**



● Brazil ● Canada ● China ● Switzerland  
● Singapore ● Taiwan ● USA

(Pie charts add to more than total number of trials because some of our trials are multinational.)

## Trial design type



Participants in the pipeline: **18,071**

Active trial participants: **236**

Trial participants treated: **7,305**


Total peer-reviewed papers expected: **75**

Peer-reviewed papers in prep: **15**

Peer-reviewed papers published: **19**



# Indications (pursuing regulatory approvals in 2025)






# A Suite of Objective Tools for Psychiatry

We have reason to believe it is possible to objectively measure emotional valence and arousal.

Combined with Mobio's objective stress measure (already validated and commercialised), objective emotional assessment will create an unbiased window into the mental wellbeing of a patient in real time, without the need for any medical hardware.





# Next 24 Months

## Platform Distribution

- 10 health systems onboarded by end of 2025
- Access >1m patients through 5k clinicians using the AmDTx platform for patient care and clinical decisions
- Broad vector data creation

## Technology Development



- Triple access objective measuring stick for mental health
- Clinical validation across five languages within traumatic brain injury, psycho-oncology, post-partum depression, and paediatric eating disorders

## Financials

- 0.5M ARR in 2024 via hospital AmDTx platform licensing and remote monitoring reimbursement codes with telehealth providers
- >1.5M ARR in 2025 / >4M ARR in 2026

## Market Access

- Platform approvals for remote-CBT, remote-CCT, remote patient monitoring
- Single-click reimbursed prescriptions





# Pre-A

Mobio has raised our US\$2M Pre-A from solid VCs in health technologies, including:



Over US\$650k in revenue signed in 2024 already from respected hospitals and telehealth providers:



Pre-A capital accelerates growth:







**Pre-A closed Dec. 31<sup>st</sup>, 2024**

Contact to discuss Series A

---

**[bechara@mobiointeractive.com](mailto:bechara@mobiointeractive.com)**